Clinical Catch-up for June 10-14
ADA: Novo Nordisk’s oral semaglutide posts another heart safety win
Lilly’s Trulicity cuts heart risks by 12%. Is it enough to fend off semaglutide?
Novo Nordisk’s Ozempic Continues to Show Superiority in Diabetes Control
Novo hopes slimmed-down bet can still win in obesity
Novo Nordisk’s semaglutide is headed toward a Lilly showdown. Will Novo speed it up?
Novo’s next big diabetes bet heads to regulators
Lilly’s under-pressure Trulicity scores with first-of-its-kind cardio outcomes win
Novo Nordisk boosts its GLP-1 score with yet more evidence for crucial semaglutide pill
Got tech ideas for diabetes? Novo wants you for its crowdsourcing challenge
Lilly makes waves with next-generation diabetes drug, but GLP-1 rivals needn’t panic: analysts
As Diabetes Market Competition Heats up, Novo Nordisk to Cut 250 Jobs in U.S.
The approval case for Novo Nordisk’s oral GLP-1 diabetes candidate keeps on building, this time with new data in patients with kidney troubles. Monday, the Danish drugmaker said that in a phase … Continue Reading Novo data buttress its oral semaglutide case, this time in kidney-impaired patients
Shares of Danish drugmaker Novo Nordisk are down about five percent this morning after the company reported an overall decline in sales during the second quarter of this year. Sales were particularly disappointing in … Continue Reading Novo Nordisk U.S. Sales Slump in 2Q and Predicts Continued Decline for 2019
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them. Cannabinoid Drug for Pancreatic Cancer Researchers with Queen Mary University of London … Continue Reading Cannabidiol and Pancreatic Cancer, Metformin, Thalidomide and More
Dive Brief: Against a backdrop of intense market competition, Novo Nordisk has rolled out a direct-to-consumer campaign for Ozempic, its once-weekly, injectable Type 2 diabetes medication. Set to the tune … Continue Reading With diabetes competitive as ever, Novo launches Ozempic DTC campaign